Justification - Federal Occupational Health (FOH) Clinical West Occupational Health Support Services
Awarded on October 31, 2025. Full description on SAM.gov.
Overview
- Posted
- December 14, 2025
- Notice type
- Justification
- Agency
- Department of Health and Human ServicesOFFICE OF THE ASSISTANT SECRETARY FOR ADMINISTRATION (ASA)
Notice details
- Office
- PROGRAM SUPPORT CENTER ACQ MGMT SVC
- Last updated
- Nov 5, 2026
- First published
- Last updated on SAM.gov
- Award date
- Oct 31, 2025
- Award amount (SAM.gov award notice)
- Not specified
Identifiers
- Solicitation number
- PSC346494-JOFOC-ClinicalWestStaffing
- Notice ID
- 61e47241a4ba4a399aed8216e9d2e1f3
Description
This contract is to provide mission-critical Clinical Staffing Services in the Western Region of the United States, consisting of occupational medicine services, medical employability and fitness for duty services that focus on assessment of the ability of the employee to meet immediate job demands, increase employee productivity and improve employee performance. Work performed under this contract will occur at multiple Federal Occupational Health (FOH) Service Provision Sites (SPSs) in the FOH Clinical West region. The states within this region include: Alaska, Arizona, California, Colorado, Hawaii, Idaho, New Mexico, Montana, Nevada, Oregon, Utah, Washington and Wyoming.
Reference the attached justification.
Award Overview
Award Number
HHSP233201800009I
Award Amount (SAM.gov award notice)
Not specified
Award Date
Oct 31, 2025
Awardee
Not specified
Delivery Order Number
75P00123F37007
Original Solicitation
Notice ID: 61e47241a4ba4a399aed8216e9d2e1f3
Posted Date: Dec 14, 2025
Original Response Deadline: Not specified
Contract Details
Contract data not yet available
Contract details typically appear within 2-4 weeks after award; DoD awards are published about 90 days after signature.
Contacts
Contracting Officer
Primary Contact
Secondary Contact
Documents
Files (1)
- Download
JOFOC West_Final_Redacted_10.2025.pdf
785 KBAdded in Justification version 3Posted
Lifecycle
- 3Version 3JustificationArchivedCurrent
Justification - Federal Occupational Health (FOH) Clinical West Occupational Health Support Services
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
The Government proposes a noncompetitive modification to Task Order 75P00123F37007, issued under Contract HHSP233201800009I, to provide interim bridge services while FOH completes the competitive follow-on acquisition and transition. The proposed modification would establish a seven-month base period, November 1, 2026 through May 31, 2027, and one five-month option, June 1 through October 31, 2027. The proposed modification will increase the total estimated cost of the task order by $6,690,504.50, from $23,999,068.73 to $30,689,573.23. Performance will be limited to the services and duration supported by the approved justification and implemented through the executed modification. Contract HHSP233201800009I / 75P00123F37007 (West) is an Indefinite Delivery Indefinite Quantity (IDIQ), Time and Materials (T&M) Task Order with ServeFed, Inc. A Determination and Findings for a T&M type task order was not found in the base contract file that was transferred from WorkSmarter to HCAS. However, a D&F approved by the CO is included in the award file with this modification. The proposed modification is necessary to maintain uninterrupted mission-essential services while the Government completes and awards the competitive follow-on acquisition. The recompete is currently under development but will not be completed before expiration of the existing contract on October 31, 2026. The Government anticipates award of the bridge modification in October 2026, using FY 2027 Service Supply funds, subject to availability and proper obligation of funds. The proposed bridge period is November 1, 2026 through October 31, 2027. The Government intends to transition to the competitively awarded follow-on contract as soon as practicable and does not intend to use the entire bridge period if transition to the successor contractor can occur earlier. The Government plans to solicit for the recompete in FY27. | 90% | Sole Source / J&A | Open |
The Government proposes a noncompetitive modification to Task Order 75P00123F37008, issued under Contract HHSP233201800009I, to provide interim bridge services while FOH completes the competitive follow-on acquisition and transition. The proposed modification would establish a six-month base period, November 1, 2026 through April 30, 2027, and one six-month option, May 1 through October 31, 2027. The proposed modification will increase the total estimated cost of the task order by $19,978,602.20, from $62,094,434.91 to $82,073,037.11. Performance will be limited to the services and duration supported by the approved justification and implemented through the executed modification. Task Order 75P00123F37008 (Clinical East), issued under IDIQ Contract HHSP233201800009I, is a time and-materials (T&M) task order with ServeFed, Inc. Before execution of the proposed modification, the Contracting Officer will confirm the applicable contract-type requirements, review the availability of any existing determination and findings (D&F), and document the basis for continued use of T&M or any proposed change in contract type. The proposed modification is necessary to maintain uninterrupted mission-essential services while the Government completes and awards the competitive follow-on acquisition. The recompete is currently under development but will not be completed before expiration of the existing contract on October 31, 2026. The Government anticipates award of the bridge modification in October 2026, using FY 2027 Service Supply funds, subject to availability and proper obligation of funds. The proposed bridge period is November 1, 2026 through October 31, 2027. The Government intends to transition to the competitively awarded follow-on contract as soon as practicable and does not intend to use the entire bridge period if transition to the successor contractor can occur earlier. The Government plans to solicit for the recompete in FY27. | 65% | Sole Source / J&A | Open |
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Seeks Industry Partners for Clinical Research Collaborations on Therapeutics, Diagnostics or Devices for Childhood Cholestatic Liver Diseases The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) of the Department of Health and Human Services (DHHS) seeks industry collaborators to provide novel therapeutic agents, diagnostic markers, biomarkers and devices for use in NIH-sponsored multi-center clinical trials and ancillary studies in patients with childhood cholestatic liver diseases, including biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, and idiopathic neonatal hepatitis; and the liver disease related complications emanating from these diseases. BACKGROUND: The Childhood Liver Disease Research and Education Network (ChiLDReN) is a multi-center consortium of 10 clinical sites in the United States plus a scientific data coordinating center funded by NIDDK to study rare childhood liver diseases that result in cholestasis, including primary sclerosing cholangitis, biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, progressive familial intrahepatic cholestasis (PFIC), bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, and idiopathic neonatal hepatitis. Five ongoing studies being conducted by ChiLDReN include: 1) A Prospective Database of Infants with Cholestasis (PROBE), a longitudinal observational study starting in infancy which has enrolled 890 infants with biliary atresia and 621 with intrahepatic cholestasis; 2) Biliary Atresia Study in Infants and Children (BASIC), a longitudinal study of children with biliary atresia both before and after liver transplant, which has enrolled over 1768 children with biliary atresia 3) Longitudinal Study of Genetic Causes of Intrahepatic Cholestasis (LOGIC), a longitudinal study of intrahepatic cholestasis diseases, which has enrolled 474 subjects with Alagille syndrome, 572 with alpha-1 antitrypsin deficiency liver disease, 355 with PFIC and 36 with bile acid defects; 4) Longitudinal study of Mitochondrial Hepatopathies (MITOHEP) with 73 participants; and 5) Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH), a study of the prognostic value of hepatic ultrasound on the development of liver fibrosis in CF, which has enrolled over 770 subjects. In addition, ChiLDReN completed a placebo-controlled clinical trial to determine if post-operative corticosteroid therapy improves serum bilirubin and survival without liver transplantation in 140 infants with biliary atresia who have undergone the Kasai surgery ("START"). Ancillary studies to evaluate the natural history, clinical outcomes and quality of life, pathogenesis, genetics and genomics, proteomics, metabolomics, lipidomics, imaging studies, and determinants of progression and severity of these cholestatic liver diseases present a variety of research collaboration opportunities. ChilDReN is also interested in conducting clinical trials of promising therapies to improve clinical outcomes for these cholestatic liver diseases. Finally, improved diagnostics or screening procedures for biliary atresia and cholestasis in infants are of great interest to ChiLDReN. STUDY GOALS: The overall goal of ChiLDReN is to determine the etiology, genetics, pathogenesis, natural history, clinical outcomes, complications, predictors of outcomes and optimal therapy of the cholestatic liver diseases. ChiLDReN studies have enrolled and are following a relatively large and well characterized population of children and young adults with these rare disorders. ChiLDReN is interested in conducting research that will lead to improved clinical outcomes in children and young adults with these cholestatic liver diseases with industry collaborators to: • Evaluate the natural history, pathogenesis, diagnosis, genetic factors, genomics, proteomics, metabolomics, lipidomics, epigenomics, imaging studies, and determinants of progression and severity of biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis. • Explore use of serum markers for fibrosis and serum markers for disease activity to predict hepatic histology either by themselves or in combination with other clinical, laboratory, genomic, proteomic, metabolomic, and lipidomic variables • Explore the utility of these serum markers as surrogate markers of therapeutic response in study subjects participating in treatment trials (e.g., START study for biliary atresia) • Investigate proprietary drugs (such as novel choleretic agents, anti-fibrogenic agents, autophagy inducers, chloride channel inducers, fat-soluble vitamin supplements, bone mineral density agents, etc.), reagents, or devices in controlled randomized clinical trials as potential diagnostics or therapies for biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis • Evaluate novel newborn or infant screening techniques or devices for biliary atresia or cholestasis. • Evaluate noninvasive imaging methods for assessing fibrosis, biliary disease, and parenchymal pathology in these diseases including but not limited to the use of elastography, nuclear magnetic resonance imaging, and molecular imaging. • Evaluate the use of cytokine assays for analyses of serum/plasma cytokine levels as markers of disease activity and as surrogate markers of histologic or clinical improvement in therapeutic trials CAPABILITY STATEMENT: Commercial organizations interested in pursuing clinical collaborations with NIDDK for childhood cholestatic liver diseases are required to submit a Capability Statement to NIDDK. The Capability Statements submitted in response to this announcement will be used to evaluate and select industry collaborators. The Capability Statement should not exceed 10 (ten) pages of narrative (not including appendices) and should include the following information: 1. A description of the therapeutic, diagnostic or device proposed to be used in the clinical research study. (Note: The proposed therapeutic or device must have been tested already in a Phase I trial in humans.) 2. The specific details of the methods to be utilized in the investigation of the pharmacologic, surgical or device intervention in patients with biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis, and a clear description of all important issues surrounding the evaluation of disease progression in these patients. 3. A detailed plan demonstrating the ability to provide sufficient quantities of the therapeutic, diagnostic or device in a timely manner for the duration of the study. 4. A description of all laboratory tests that are needed, including assays and required amount of specimens, to determine specific biomarker levels along with appropriate methods for performing such tests. 5. A description of other core facilities and interactions with core facilities that are needed for the study. 6. Dosing and pharmacokinetic data from human studies for any novel therapeutics. 7. Adverse event profile for the proposed therapeutic or device. 8. A description of the practices and procedures that would be used to assure patient privacy and maintain confidentiality of data obtained from the study. 9. (Optional) Outcome measures of interest to the organization. The specifics of the proposed outcome measures should include but not be limited to treatment and evaluation of biliary atresia, alpha-one antitrypsin deficiency, cystic fibrosis liver disease, Alagille syndrome, PFIC, bile acid synthesis defects, mitochondrial respiratory chain and fatty acid oxidation defects, primary sclerosing cholangitis, or idiopathic neonatal hepatitis. 10. Any other resources the organization proposes to commit to the collaboration (in addition to the proposed therapeutic, diagnostic or device), which may include any of the following: equipment, reagents, supplies, access to facilities, personnel or services, and, if appropriate, funding (pursuant to a Cooperative Research and Development Agreement (CRADA) authorized under 15 U.S.C. § 3710a), to help support the conduct of the clinical study. 11. Affirmative statements that the organization: a. agrees to provide a Letter of Cross Reference to the Drug, Biologic or Device Master File for the proposed therapeutic or device, which will be included with any US FDA filing by the IND or IDE Sponsor of the ChiLDReN study; b. agrees to have the proposed therapeutic, diagnostic or device used in ChiLDReN-developed protocols which will be conducted by the ChiLDReN research network for which the study data collection and analysis will be performed by the ChiLDReN Scientific and Data Coordinating Center; c. agrees to assure patient privacy and will maintain confidentiality of data obtained from the study; d. agrees to share all safety data from other studies involving the proposed therapeutic or device as well as relevant efficacy data from other studies (updated Investigator Brochure, etc) with the ChiLDReN; e. understands that because the ChiLDReN network is supported by NIDDK funding, the study results will be published and therefore agrees to the prompt publication of research results from the clinical study using the organization's proposed therapeutic, diagnostic or device; and f. understands that the clinical study will be conducted under an agreement with NIDDK which must adhere to PHS intellectual property policies (see: http://www.ott.nih.gov/policy/phspat_policy.aspx). SUBMISSION: Capability Statements received by NIDDK will be considered. Prospective collaborators may be invited to attend, at their own expense, a ChiLDReN Steering Committee meeting to be held in the Baltimore-Washington, DC area to discuss the information in their Capability Statement with the Steering Committee members. NOTE:NO FUNDS WILL BE PROVIDED BY NIDDK TO ANY ORGANIZATION SELECTED FOR THIS CLINICAL RESEARCH COLLABORATION OPPORTUNITY. SUBMISION AND INQUIRIES: Submit Capability Statements to: NOO Coordinator, National Institute of Diabetes and Digestive and Kidney Diseases e-mail: niddkottdip@niddk.nih.gov For Scientific Inquiries contact: Edward Doo, MD Director, Liver Diseases Research Program Division of Digestive Diseases and Nutrition, NIDDK 6707 Democracy Blvd., Room 6149 Bethesda, MD 20892-5450 Telephone: (301) 451-4524 FAX: (301) 480-8300 e-mail: dooe@niddk.nih.gov Katrina Loh, MD Director, Pediatric Gastrointestinal and Liver Diseases Division of Digestive Diseases and Nutrition, NIDDK 6707 Democracy Blvd., Room 6148 Bethesda, MD 20892-5450 Telephone: (301) 827-1079 FAX: (301) 480-8300 e-mail: katrina.loh@nih.gov For Inquiries Regarding Partnering with NIDDK (Intellectual Property Matters and Collaboration Agreements) contact: Agnes Rooke, JD Technology Advancement Office NIDDK, NIH, HHS Telephone: 301-451-6072 e-mail: Agnes.Rooke@nih.gov This Notice of Opportunity is also posted at: http://techdev.niddk.nih.gov/collabs.shtml. | 56% | Special Notice | 05/31/2029 |
This is a PRESOLICITATION NOTICE for the upcoming Solicitation No. 75H70927BAO-005-RFP for multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) contracts to provide Physician, Advanced Practice Provider (APP), and Allied Health Professional staffing services in support of multiple Indian Health Service (IHS) facilities and operations located within the Billings Area in Montana. The Government anticipates releasing the solicitation on or about November 23, 2026, with a response period of approximately 45 calendar days. The solicitation and all amendments for this Request for Proposals will be posted on https://sam.gov under Contract Opportunities. A full scope of work will be included in the solicitation documents. Additional details can be found in the solicitation when it is posted to https://sam.gov. SCOPE OF WORK: The purpose of this acquisition is to ensure uninterrupted access to clinical care through contracted healthcare providers who can fill urgent and long-term staffing gaps. The contractor shall furnish credentialed professionals across a range of disciplines to provide in-person healthcare services aligned with facility-specific needs within the Billings Area. These professionals will be fully integrated into existing care teams at IHS hospitals and clinics, participating in direct patient care, documentation, care coordination, and quality assurance activities as required by facility standards and accreditation. Specialized fields include the following: Anesthesiologist Certified Registered Nurse Anesthetist (CRNA) Emergency Medicine Physician (ABEM Certified) Family Medicine Physician General Surgeon Hospitalist Internal Medicine Physician Mid Wife Nurse Practitioner (APN) Obstetrician/Gynecology Physician (OB/GYN) Orthopedic Physician Pediatrician (Pediatric Physician) Physician Assistant Podiatrist Respiratory Therapist (RT) LOCATIONS: All facilities are located in Montana. Services under this acquisition will be performed at the following IHS Billings Area service units and facilities: Blackfeet Service Unit (BFSU): Blackfeet Community Hospital; Browning, Montana Heart Butte Health Station; Heart Butte, Montana Crow Service Unit (CSU): Crow/Northern Cheyenne Hospital; Crow Agency, Montana Lodge Grass Health Clinic; Lodge Grass, Montana Pryor Health Station; Pryor, Montana Fort Belknap Service Unit (FBSU): Fort Belknap Hospital; Harlem, Montana Eagle Child Health Station; Hays, Montana Fort Peck Service Unit (FPSU): Verne E. Gibbs Clinic; Poplar, Montana Chief Redstone Clinic; Wolf Point, Montana Northern Cheyenne Service Unit (NCSU): Northern Cheyenne Health Clinic; Lame Deer, Montana PERIOD OF PERFORMANCE: A base period of one (1)year plus one (1) year option period. ESTIMATED TOTAL VALUE (All Awards Combined): $86,090,000, inclusive of the base period and one option year. SITE VISIT: Details regarding the Site Visit, if any, will be included in the solicitation. CONTRACT TYPE: The Indian Health Service intends to award multiple-award Indefinite Delivery/Indefinite Quantity (IDIQ) Fixed Price and Labor Hour contracts in support of this requirement. Awarded contractors will compete for individual task orders in accordance with the ordering procedures to be established in the final contract award. A minimum will be identified in the final solicitation publication. Awards will be made on a best-value tradeoff basis in accordance with FAR Part 15. Specific evaluation factors and their relative importance will be detailed in the solicitation. This procurement is being conducted as a 100% set-aside for Indian Economic Enterprises (IEEs) pursuant to the Buy Indian Act 25 U.S.C. 47, under North American Industry Classification System (NAICS) code 621399, Offices of All Other Miscellaneous Health Practitioners. Only offerors verified as Indian Economic Enterprises in accordance with IHS's IEE verification requirements will be eligible to submit proposals and receive award. Registration in the System for Award Management (SAM) database is mandatory to be considered for award. Offerors may obtain information on registration and annual confirmation requirements via the internet at: https://sam.gov. Contractors are encouraged to complete SAM registration as soon as possible; the Government may not delay award for the purpose of allowing a contractor additional time to register in SAM. It is the responsibility of the contractor to check https://sam.gov frequently for any amendments or changes to the solicitation. Hard copy documents will NOT be available – all documents for proposal purposes will be posted at the website for download by interested parties. NOTE: ALL DATES ARE SUBJECT TO CHANGE. SEE SOLICITATION FOR OFFICIAL DATES, TIMES, AND DEADLINES. This notice is for informational purposes only and is NOT a request for submission of offers. No other information is available until issuance of the solicitation itself. No bidder list is maintained. Interested bidders should follow this solicitation notice on https://sam.gov to receive email notifications of any updates to the initial notice including any subsequent amendments. No additional information is available other than what is noted herein. Firms are instructed not to call requesting more information. | 51% | Pre-Solicitation | 10/29/2026 |
This is a notice of intent to award a sole source contract with Johns Hopkins Bayview Medical Center, Inc., to extend the period of performance for the clinical services and resources necessary to maintain the research operation of the NIDA IRP Clinical Research Program. The Government proposes to award an additional twelve (12) month contract with the period of performance: December 31, 2026 through January 31, 2027. The determination by the Government to award a contract without providing for full and open competition is based upon the market research conducted. Specifically, Johns Hopkins Bayview Medical Center is the only vendor in the marketplace that can provide the services required by NIDA. | 51% | Combined Synopsis | 11/25/2026 |
Additional Details
Solicitation Number
PSC346494-JOFOC-ClinicalWestStaffing
Archive Date
Jan 13, 2026
Office Address
ROCKVILLE, MD, 20857